Esr/ers white paper on lung cancer screening
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Esr/ers white paper on lung cancer screening
Author(s) :
Kauczor, Hans-Ulrich [Auteur]
Bonomo, Lorenzo [Auteur]
Gaga, Mina [Auteur]
Nackaerts, Kristiaan [Auteur]
Peled, Nir [Auteur]
Prokop, Mathias [Auteur]
Remy, Martine [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Von Stackelberg, Oyunbileg [Auteur]
Sculier, Jean-Paul [Auteur]
Bonomo, Lorenzo [Auteur]
Gaga, Mina [Auteur]
Nackaerts, Kristiaan [Auteur]
Peled, Nir [Auteur]
Prokop, Mathias [Auteur]
Remy, Martine [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Von Stackelberg, Oyunbileg [Auteur]
Sculier, Jean-Paul [Auteur]
Journal title :
The European respiratory journal
Abbreviated title :
Eur. Resp. J.
Volume number :
46
Pages :
28-39
Publication date :
2015-07-01
ISSN :
0903-1936
English keyword(s) :
Mesh:Pulmonary Medicine/methods
Mesh:Societies
Mesh:Medical
Mesh:Smoking Cessation
Mesh:Smoking
Mesh:Risk Factors
Mesh:Registries
Mesh:Pulmonary Medicine/standards
Mesh:Pulmonary Disease
Mesh:Chronic Obstructive/complications
Mesh:Probability
Mesh:Middle Aged
Mesh:Mass Screening/methods
Mesh:Lung Neoplasms/diagnosis*
Mesh:Humans
Mesh:Guidelines as Topic
Mesh:False Positive Reactions
Mesh:Europe
Mesh:Early Detection of Cancer*
Mesh:Cost-Benefit Analysis
Mesh:Clinical Trials as Topic
Mesh:Biological Specimen Banks
Mesh:Aged
Mesh:Societies
Mesh:Medical
Mesh:Smoking Cessation
Mesh:Smoking
Mesh:Risk Factors
Mesh:Registries
Mesh:Pulmonary Medicine/standards
Mesh:Pulmonary Disease
Mesh:Chronic Obstructive/complications
Mesh:Probability
Mesh:Middle Aged
Mesh:Mass Screening/methods
Mesh:Lung Neoplasms/diagnosis*
Mesh:Humans
Mesh:Guidelines as Topic
Mesh:False Positive Reactions
Mesh:Europe
Mesh:Early Detection of Cancer*
Mesh:Cost-Benefit Analysis
Mesh:Clinical Trials as Topic
Mesh:Biological Specimen Banks
Mesh:Aged
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based ...
Show more >Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and the European Respiratory Society recommend lung cancer screening in comprehensive, quality-assured, longitudinal programmes within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. Minimum requirements include: standardised operating procedures for low dose image acquisition, computer-assisted nodule evaluation, and positive screening results and their management; inclusion/exclusion criteria; expectation management; and smoking cessation programmes. Further refinements are recommended to increase quality, outcome and cost-effectiveness of lung cancer screening: inclusion of risk models, reduction of effective radiation dose, computer-assisted volumetric measurements and assessment of comorbidities (chronic obstructive pulmonary disease and vascular calcification). All these requirements should be adjusted to the regional infrastructure and healthcare system, in order to exactly define eligibility using a risk model, nodule management and quality assurance plan. The establishment of a central registry, including biobank and image bank, and preferably on a European level, is strongly encouraged.Show less >
Show more >Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and the European Respiratory Society recommend lung cancer screening in comprehensive, quality-assured, longitudinal programmes within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. Minimum requirements include: standardised operating procedures for low dose image acquisition, computer-assisted nodule evaluation, and positive screening results and their management; inclusion/exclusion criteria; expectation management; and smoking cessation programmes. Further refinements are recommended to increase quality, outcome and cost-effectiveness of lung cancer screening: inclusion of risk models, reduction of effective radiation dose, computer-assisted volumetric measurements and assessment of comorbidities (chronic obstructive pulmonary disease and vascular calcification). All these requirements should be adjusted to the regional infrastructure and healthcare system, in order to exactly define eligibility using a risk model, nodule management and quality assurance plan. The establishment of a central registry, including biobank and image bank, and preferably on a European level, is strongly encouraged.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Université de Lille
Université de Lille
Submission date :
2019-12-09T16:51:46Z